Teva Pharmaceutical Industries Ltd. has launched the generic equivalent to Baraclude (entecavir) tablets, 0.5 mg and 1mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity, according to the company.

Baraclude, a drug to treat chronic hepatitis B, is marketed by Bristol-Myers Squibb. It had annual sales of approximately $328 million in the United States, according to IMS data as of June 2014, and as reported by Teva.

Source: Teva Pharmaceutical Industries